SCHEMBL21519620

SCHEMBL21519620

Cc1cc(=O)nc(NN=Cc2ccc(Cl)c(Cl)c2)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.53
▸ LMNA P02545 4/20 0.53
▸ GAA P10253 4/20 0.51
▸ ALPL P05186 1/20 0.51
▸ ALPI P09923 1/20 0.51
▸ ALPG P10696 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 5/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ MMP10 P09238 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21519616 1.00 MAPT (0.53) MAPTLMNAGAAALPLALPI
SCHEMBL21519374 0.82 KMT2A (0.46) MAPTLMNAGAAALPLALPI
SCHEMBL21519372 0.82 KMT2A (0.46) MAPTLMNAGAAALPLALPI
SCHEMBL21519484 0.81 MAPT (0.52) MAPTLMNAGAAALPLALPI
SCHEMBL21519487 0.81 MAPT (0.52) MAPTLMNAGAAALPLALPI
SCHEMBL21519445 0.81 KMT2A (0.52) MAPTLMNAGAAALPLALPI
SCHEMBL21519447 0.81 KMT2A (0.52) MAPTLMNAGAAALPLALPI
SCHEMBL21519560 0.80 KMT2A (0.70) MAPTLMNAGAAALDH1A1KDM4E
SCHEMBL21519562 0.80 KMT2A (0.70) MAPTLMNAGAAALDH1A1KDM4E
SCHEMBL21519665 0.78 KMT2A (0.58) MAPTLMNAGAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006294-B2 Therapeutic compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-06-11 — — US disclosed
US-20190330157-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330157-A1 THERAPEUTIC COMPOUNDS OPRL1, INA, OGFR MAPT 3826/4885LMNA 1901/4885GAA 2851/4885
US-12006294-B2 Therapeutic compounds OPRL1, INA, OGFR MAPT 3826/4885LMNA 1901/4885GAA 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback